
Embattled biotech firm Orphazyme announced last week that several potential buyers had made bids to buy all of the company’s assets and operations.
Orphazyme Deputy Chair Bo Jesper Hansen now tells MedWatch that the bids suggest potential buyers will continue chasing FDA approval of the firm’s lead asset, arimoclomol.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app